Aktuellt
SENASTE
Redeye comments on Spago’s Q1 2022 report and the company update presented yesterday. Overall, we are encouraged by the company’s progress, driving the SPAGOPIX-01 trial towards completion while simultaneously closing in on clinical trials with Tumorad. We view finishing SPAGOPIX-01 and Tumorad entering the clinic as positive catalysts for Spago’s share, potentially partly counteracted by a capital need later this year, according to our estimates.
LÄS MER
